Top 25 Companies in Global Oncolytic Virus Market: Global Share, Market Size, Revenue Report (2024–2035)
RELEASE DATE: Apr 2026 Author: Spherical InsightsRequest Free Sample Speak to Analyst
Introduction
The global oncolytic virus market refers to the segment of the biotechnology and oncology therapeutics industry that focuses on the development and application of viruses engineered or naturally occurring to selectively infect and destroy cancer cells while sparing healthy tissues. The mechanism of oncolytic viruses involves their replication within tumor cells which results in cell lysis to create an immune response that fights against tumors. The medical field currently investigates these treatments as effective cancer treatment methods which can be used independently or together with immune checkpoint inhibitor therapies. The market experiences continuous growth because more people develop cancer and patients require better targeted treatment solutions. The application of genetic engineering and virology research advancements enables researchers to create oncolytic virus treatments which demonstrate improved safety and treatment outcomes. The growth of clinical trials together with partnerships between biotech companies and research institutions drives the progress of product development. The present trend toward personalized medicine together with immuno-oncology research establishes oncolytic viruses as essential components of current cancer treatment methods.
Navigate Future Markets with Confidence: Insights from Spherical Insights LLP
The insights presented in this blog are derived from comprehensive market research conducted by Spherical Insights LLP, a trusted advisory partner to leading global enterprises. Backed by in-depth data analysis, expert forecasting, and industry-specific intelligence, our reports empower decision-makers to identify strategic growth opportunities in fast-evolving sectors. Clients seeking detailed market segmentation, competitive landscapes, regional outlooks, and future investment trends will find immense value in the full report. By leveraging our research, businesses can make informed decisions, gain a competitive edge, and stay ahead in the transition toward sustainable and profitable solutions.
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Oncolytic Virus Market.
Market Segmentation
Global Oncolytic Virus Market Size, Share, By Virus Type (Adenovirus, Herpes Simplex Virus, Vaccinia Virus, Reovirus), By Application (Melanoma, Prostate Cancer, Breast Cancer, Lung Cancer, Others), By End User (Hospitals, Cancer Research Institutes, Specialty Clinics), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2024–2035
Oncolytic Virus Market Size & Statistics
- The Market Size for Oncolytic Virus Was Estimated to be worth USD 19.2 Million in 2024.
- The Market is Going to Expand at a CAGR of 7.02 % between 2025 and 2035.
- The Global Oncolytic Virus Market Size is anticipated to reach USD 40.5 Million by 2035.
- North America is expected to generate the highest demand during the forecast period in the Oncolytic Virus Market
- Asia Pacific is expected to grow the fastest during the forecast period in the Oncolytic Virus Market.
Regional growth and demand
Asia Pacific is expected to grow the fastest during the forecast period in the oncolytic virus market. Asia Pacific is expected to grow fastest due to increasing cancer prevalence, development in healthcare infrastructure, investment in biotechnology research, and awareness of advanced cancer treatments in countries such as China, Japan, South Korea, and India. Clinical research activities in the region and government initiatives in biotechnology development also fuel market growth.
North America is expected to generate the highest demand during the forecast period in the oncolytic virus market. North America is expected to generate the highest demand due to its advanced healthcare facilities, presence of biotech and pharmaceutical companies, investment in cancer research, and number of clinical trials. These factors contribute to its dominance in the market.
Ready to lead the Oncolytic Virus Market ?
Discover the regional trends and growth factors shaping the industry. We’re here to assist with expert, personalized data.
Call +1 303 800 4326 or Send us a message for a personalized consultation.
Top 10 Trends in the Oncolytic Virus Market
- Increasing Adoption of Oncolytic Viruses in Cancer Immunotherapy
- Growing Combination Therapies with Immune Checkpoint Inhibitors
- Advancements in Genetic Engineering of Viruses
- Expansion of Clinical Trials and Pipeline Development
- Rising Focus on Personalized Cancer Treatment Approaches
- Increasing Regulatory Approvals for Novel Therapies
- Growing Investment in Biotechnology and Oncology Research
- Development of Targeted Delivery Mechanisms
- Rising Collaboration Between Biotech Firms and Research Institutes
- Expansion of Oncolytic Virus Applications Across Multiple Cancer Types
- Increasing Adoption of Oncolytic Viruses in Cancer Immunotherapy
Oncolytic viruses function as immunotherapy agents because they destroy cancer cells while activating the body's immune system. The treatment becomes more effective because of this double function which medical professionals now use to treat patients with cancer.
- Growing Combination Therapies with Immune Checkpoint Inhibitors
The medical field has started to use oncolytic viruses together with immune checkpoint inhibitors because this method leads to better treatment results. The combination methods work to boost immune system actions against tumors while they also give patients better results than separate treatment methods.
- Advancements in Genetic Engineering of Viruses
Scientists now possess the ability to create exact genetic alterations in viruses which enhances their safety and targeting capabilities and their ability to treat medical conditions. Scientists design engineered viruses to infect only tumor cells while they transmit therapeutic genes to those cells.
- Expansion of Clinical Trials and Pipeline Development
There is a significant increase in clinical trials evaluating oncolytic virus therapies across various cancer types. The expanding pipeline demonstrates that this treatment method will experience substantial future growth because people now have greater trust in its effectiveness.
- Rising Focus on Personalized Cancer Treatment Approaches
Oncolytic virus therapies are being tailored to individual patient profiles, aligning with the broader trend of personalized medicine. This method targets specific tumor features to deliver better treatment results which improves patient health outcomes.
Empower your strategic planning:
Stay informed with the latest industry insights and market trends to identify new opportunities and drive growth in the Oncolytic Virus market. To explore more in-depth trends, insights, and forecasts, please refer to our detailed report.
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Oncolytic Virus Market.
Top 25 Companies Leading the Oncolytic Virus Market
- Amgen Inc.
- Oncorus, Inc.
- Replimune Group, Inc.
- Sorrento Therapeutics, Inc.
- Targovax ASA
- Transgene S.A.
- PsiOxus Therapeutics Ltd.
- Lokon Pharma AB
- Oncolytics Biotech Inc.
- Viralytics Ltd.
- Merck & Co., Inc.
- Roche Holding AG
- Pfizer Inc.
- Bristol-Myers Squibb Company
- AstraZeneca plc
- Takeda Pharmaceutical Company Limited
- Johnson & Johnson
- Imugene Limited
- CG Oncology, Inc.
- Virogin Biotech Ltd.
- Genelux Corporation
- Vyriad, Inc.
- KalVista Pharmaceuticals, Inc.
- ImmVirX Pty Ltd.
- IconOVir Bio, Inc.
- Amgen Inc.
Headquarters: Thousand Oaks, California, USA
Amgen Inc. operates as the top biotechnology firm which leads the oncolytic virus industry through its FDA-approved Imlygic treatment for melanoma. The company develops biologics and targeted therapies for cancer treatment. The oncolytic virus platform uses genetically modified viruses for two purposes which include targeting cancer cells and activating immune system responses. Amgen dedicates significant resources to oncology research and combination therapy development. The company established itself as a market leader through its extensive product range and successful business operations.
- Oncorus, Inc.
Headquarters: Cambridge, Massachusetts, USA
Oncorus, Inc. is a biotechnology company that operates at the clinical stage and develops advanced oncolytic viral immunotherapy treatments. The company uses its unique viral platforms to improve tumor targeting and immune response activation. The company develops engineered viruses which deliver therapeutic substances to cancer tumors. Oncorus uses its viral engineering research to develop safer and more effective treatment solutions. The company's research-based methods establish it as an important force in the developing field of oncolytic virus research.
- Replimune Group, Inc.
Headquarters: Woburn, Massachusetts, USA
Replimune Group, Inc. specializes in developing oncolytic immunotherapies based on genetically modified herpes simplex viruses. The company develops therapies which achieve two objectives through their ability to kill cancer cells and their potential to generate entire-system immune defenses against tumors. The company is conducting clinical trials to test its primary drug candidates which target different types of cancer. Replimune is proceeding to investigate combination treatments which will include immune checkpoint inhibitors. The company competes in the market through its advanced clinical development program and its unique business model.
- Sorrento Therapeutics, Inc.
Headquarters: San Diego, California, USA
Sorrento Therapeutics, Inc. conducts its operations as a biopharmaceutical firm which focuses on creating groundbreaking treatments through its development of oncolytic virus-based therapeutic methods. The company develops immuno-oncology treatments which use viral platforms to specifically target and eliminate cancer cells. The company uses antibody-based therapies together with virotherapy methods to improve treatment results. Sorrento establishes its oncology pipeline through research activities and strategic partnerships which support its business development efforts. The company maintains multiple treatment options which enable it to compete in the oncolytic virus industry.
- Targovax ASA
Headquarters: Oslo, Norway
Targovax ASA functions as a biotechnology enterprise that operates at the clinical development stage which creates oncolytic virus treatments and cancer immunotherapy solutions. The company develops viral vectors designed to stimulate immune responses and target tumor cells. The company develops treatments that target solid tumors while combining different treatment methods. Targovax develops personalized medicine solutions together with biomarker-based development methods. The company established itself as a major market competitor through its targeted research initiatives and successful clinical development efforts.
Are you ready to discover more about the oncolytic virus market?
The report provides an in-depth analysis of the leading companies operating in the global oncolytic virus market. It includes a comparative assessment based on their product portfolios, business overviews, geographical footprint, strategic initiatives, market segment share, and SWOT analysis. Each company is profiled using a standardized format that includes:
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Oncolytic Virus Market.
Company Profiles
- Amgen Inc.
- Business Overview
- Company Snapshot
- Products Overview
- Company Market Share Analysis
- Company Coverage Portfolio
- Financial Analysis
- Recent Developments
- Merger and Acquisitions
- SWOT Analysis
- Oncorus, Inc.
- Replimune Group, Inc.
- Sorrento Therapeutics, Inc.
- Targovax ASA
- Transgene S.A.
- PsiOxus Therapeutics Ltd.
- Lokon Pharma AB
- Oncolytics Biotech Inc.
- Viralytics Ltd.
- Others.
Conclusion
The worldwide oncolytic virus sector maintains its continuous development because of the rising cancer rates and increasing need for precise cancer treatments and the progress of genetic engineering and virotherapy technologies. Oncolytic virus therapies offer a new and successful method that enables precise cancer cell elimination while promoting protective immune system responses which lead to better treatment results. The therapeutic effectiveness and market opportunity of the industry improves through the progress of viral engineering and the rise of clinical research and the creation of treatments that combine immune checkpoint inhibitors with other therapies. Amgen Inc. and Oncorus Inc. and Replimune Group Inc. and Sorrento Therapeutics Inc. and Targovax ASA have established worldwide research operations to meet the developing needs of cancer therapies. The use of oncolytic viruses in cancer treatments enables doctors to provide specific medical care while they help advance immuno-oncology research which leads to better results for patients across the globe.
Our Report
https://www.sphericalinsights.com/reports/italy-seed-treatment-market
https://www.sphericalinsights.com/reports/italy-compound-feed-market
https://www.sphericalinsights.com/reports/italy-data-center-market
https://www.sphericalinsights.com/reports/italy-food-colorants-market
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI. Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?